Hispanic, black, and Asian women are more likely than white women to receive neoadjuvant chemotherapy.
Interest in neoadjuvant chemotherapy for operable, HER2-positive, or triple-negative breast cancer (TNBC) has increased with the availability of new HER2-directed therapies and the potential for chemotherapies to translate an increased pathologic complete response (pCR) rate into improved overall survival (OS). However, whether the likelihood of attaining a pCR differs among racial groups receiving preoperative therapy is unclear.
To further examine this issue, investigators interrogated the National Cancer Database (NCDB) to analyze women with stage 1 to 3 breast cancer diagnosed in 2010 and 2011. A total of 27,300 patients (22.5% of the total database) were determined to have received neoadjuvant chemotherapy. The outcome evaluated was pCR…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)